Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation.
Renin-angiotensin system blockade retards the progression of diabetic and non-diabetic chronic kidney disease of the native kidneys. Though most patients suffer from a significant renal insufficiency (chronic kidney disease stage III) and a concomitant heart disease after renal transplantation, there is up to now no evidence supporting the use of inhibitors of the renin-angiotensin system in these patients. We wish to summarize the available evidence on the use of inhibitors of the renin-angiotensin system after renal transplantation. We specifically discuss potential beneficial as well as adverse effects of a renin-angiotensin system blockade. In addition, we review their influence on morphologic and biochemical markers as well as on renal function, graft and patient survival after renal transplantation.
Morath
C
C
Department of Nephrology, University of Heidelberg, Heidelberg, Germany. christian.morath@med.uni-heidelberg.de
Schmied
B
B
Mehrabi
A
A
Weitz
J
J
Schmidt
J
J
Werner
J
J
Buchler
M W
MW
Morcos
M
M
Nawroth
P P
PP
Schwenger
V
V
Doehler
B
B
Opelz
G
G
Zeier
M
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D006085:Graft Survival; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D016030:Kidney Transplantation; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors